EGFR and non-small cell lung carcinoma: While in case of CML the presence of the fusion gene BCR-ABL is pathognomonic of the disease[4] and in case of melanoma about 60% of the tumors contain the relevant BRAF V600E mutation[5, 6], activating EGFR mutations and EML4-ALK gene fusions are present in slightly over 10% and less than 5%, respectively, of non-small cell lung cancer patients[7].